KRAS and neoplasm: In addition, amplification of PIK3CA and FGFR2 in T2 and T3, combined with activating mutations in KRAS and PIK3CA in T1−3, indicates a critical role for the RAS-PI3K axis in tumor survival through multiple rounds of radiotherapy [37].